These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14978537)

  • 1. [Concept and validation of a simple model of the intrathyroidal iodine kinetics].
    Rink T; Bormuth FJ; Braun S; Zimny M; Schroth HJ
    Nuklearmedizin; 2004 Feb; 43(1):21-5. PubMed ID: 14978537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithium as an adjunct to radioiodine therapy in Graves' disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not?
    Dunkelmann S; Künstner H; Nabavi E; Eberlein U; Groth P; Schümichen C
    Nuklearmedizin; 2006; 45(5):213-8; quiz N51-2. PubMed ID: 17043732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves' disease.
    Dunkelmann S; Kuenstner H; Nabavi E; Rohde B; Groth P; Schuemichen C
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):228-36. PubMed ID: 17021811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
    Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
    Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Change of 99m technetium-pertechnetate uptake by the thyroid under suppression (TcTus) induced by optimization of iodine supply in Germany].
    Reinhardt MJ; Trupkovic T; Schumacher T; Krause TM; Oexle C; Moser E
    Nuklearmedizin; 1998; 37(6):202-7. PubMed ID: 9770714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
    Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
    Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease.
    Van Isselt JW; de Klerk JM; Koppeschaar HP; Van Rijk PP
    Nucl Med Commun; 2000 Jul; 21(7):609-16. PubMed ID: 10994662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [F-qi-FDG PET of the thyroid gland in Graves' disease].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease.
    van Isselt JW; Broekhuizen-de Gast HS
    Hell J Nucl Med; 2010; 13(1):2-5. PubMed ID: 20411161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid echogenicity: A clue to precise individual dosimetry in radioiodine therapy of hyperthyroidism.
    Marković V; Eterović D; Stipanović P; Punda A
    Med Hypotheses; 2011 Feb; 76(2):153-6. PubMed ID: 20889262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves' disease.
    Traino AC; Xhafa B
    Med Phys; 2009 Apr; 36(4):1212-8. PubMed ID: 19472628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of physiological and pharmacological amounts of iodine on the 131I uptake of the thyroid gland--a model calculation].
    Wellner U; Alef K; Schicha H
    Nuklearmedizin; 1996 Dec; 35(6):251-63. PubMed ID: 8999424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Spectrometric assessment of thyroid depth within the radioiodine test].
    Rink T; Bormuth FJ; Schroth HJ; Braun S; Zimny M
    Nuklearmedizin; 2005; 44(5):192-6. PubMed ID: 16395494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uninhibited thyroidal uptake of radioiodine despite iodine excess in amiodarone-induced hypothyroidism.
    Wiersinga WM; Touber JL; Trip MD; van Royen EA
    J Clin Endocrinol Metab; 1986 Aug; 63(2):485-91. PubMed ID: 3013921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (
    Szumowski P; Mojsak M; Abdelrazek S; Sykała M; Amelian-Fiłonowicz A; Jurgilewicz D; Myśliwiec J
    Endocrine; 2016 Dec; 54(3):751-756. PubMed ID: 27553050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of stable iodine on the uptake of the thyroid--model versus experiment].
    Weber K; Wellner U; Voth E; Schicha H
    Nuklearmedizin; 2001 Feb; 40(1):31-7. PubMed ID: 11373936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
    Baczyk M; Junik R; Ziemnicka K; Sowiński J
    Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
    Traino AC; Di Martino F; Lazzeri M
    Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scintigraphy with 99mTc-pertechnetate in the evaluation of functional thyroidal autonomy.
    Meller J; Becker W
    Q J Nucl Med; 1999 Sep; 43(3):179-87. PubMed ID: 10568133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.